Senator Cory Booker Declares Cannabis Safer Than Fast Food Amid National Drug Policy Shifts

A week marked by bold statements and legislative moves has spotlighted the evolving landscape of U.S. cannabis and psychedelic regulation. Senator Cory Booker (D-NJ) captured national attention when he quipped that cannabis is safer than McDonald's french fries, punctuating ongoing debates about marijuana scheduling and public health. "I am the leader in the Senate for descheduling marijuana, but we should schedule McDonald’s french fries," Booker joked, underscoring the shifting perceptions around cannabis safety as compared to everyday consumer products

At the federal level, President Donald Trump issued a sweeping executive order to promote research and expand access to psychedelics such as psilocybin, ibogaine, and MDMA for mental health treatment. The move drew praise from a diverse group of lawmakers and celebrities, including Sen. Lindsey Graham (R-SC), California Governor Gavin Newsom (D), and rapper Nicki Minaj. However, Trump also expressed frustration with the Department of Justice, accusing it of "slow-walking" the marijuana rescheduling process initiated under his directive four months ago

Meanwhile, a bipartisan group of senators introduced a bill allowing states and Indian tribes to opt out of a looming federal ban on hemp-derived THC products, set to take effect in November. This legislative push, led by Sens. Rand Paul (R-KY), Amy Klobuchar (D-MN), and Joni Ernst (R-IA), reflects growing concern about federal overreach and the importance of state-level autonomy in cannabis regulation. In Louisiana, the Senate approved a pilot program to use opioid settlement funds for psychedelic-assisted therapy trials, aiming to explore alternative treatments for mental health and addiction

Public opinion continues to drive the conversation, with a new poll showing that 75 percent of Texas voters support legal medical marijuana, spanning Democrats, Republicans, and independents. Yet, many Texans remain unaware of the state's limited medical cannabis program. Parallel to this, research published this week found that medical cannabis patients reduced their use of other prescription drugs by an average of 84.5 percent, including significant decreases in opioid, sleep aid, and antidepressant usage

On the regulatory front, several states enacted significant changes: New Jersey restricted the sale of intoxicating hemp THC products to licensed marijuana dispensaries, Colorado regulators launched enforcement actions against illegal hemp sales, and Massachusetts froze new cannabis cultivation licenses. Retail data also reflected cannabis's economic impact, with Missouri reporting $131.1 million in legal marijuana sales in March. In the private sector, companies like WM Technology, Inc. and Decibel Cannabis Company Inc. released quarterly revenue reports, highlighting ongoing industry growth amidst regulatory change

From the perspective of OG Lab, these developments signal a pivotal moment for cannabis and psychedelic policy in the U.S. The convergence of bipartisan legislative initiatives, shifting public attitudes, and expanding clinical research is likely to accelerate reform efforts nationwide. As lawmakers debate federal-state dynamics and regulators respond to new market realities, the cannabis industry should prepare for significant changes in both policy and public perception in the coming months